T-Lymphocytes, Regulatory
"T-Lymphocytes, Regulatory" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
CD4-positive T cells that inhibit immunopathology or autoimmune disease in vivo. They inhibit the immune response by influencing the activity of other cell types. Regulatory T-cells include naturally occurring CD4+CD25+ cells, IL-10 secreting Tr1 cells, and Th3 cells.
| Descriptor ID |
D050378
|
| MeSH Number(s) |
A11.118.637.555.567.550.500.700 A11.118.637.555.567.569.200.700 A11.118.637.555.567.569.500.700 A15.145.229.637.555.567.550.500.700 A15.145.229.637.555.567.569.200.700 A15.145.229.637.555.567.569.500.700 A15.382.490.555.567.550.500.700 A15.382.490.555.567.569.200.700 A15.382.490.555.567.569.500.700
|
| Concept/Terms |
T-Lymphocytes, Regulatory- T-Lymphocytes, Regulatory
- T Lymphocytes, Regulatory
- Regulatory T-Lymphocytes
- Regulatory T Lymphocytes
- Regulatory T-Lymphocyte
- T-Lymphocyte, Regulatory
- Regulatory T-Cells
- Regulatory T Cells
- T-Cells, Regulatory
- T Cells, Regulatory
- Treg Cells
- Cell, Treg
- Cells, Treg
- Treg Cell
Th3 Cells- Th3 Cells
- Cell, Th3
- Cells, Th3
- Th3 Cell
Suppressor T-Lymphocytes, Naturally-Occurring- Suppressor T-Lymphocytes, Naturally-Occurring
- Naturally-Occurring Suppressor T-Lymphocyte
- Naturally-Occurring Suppressor T-Lymphocytes
- Suppressor T Lymphocytes, Naturally Occurring
- Suppressor T-Lymphocyte, Naturally-Occurring
- Suppressor T-Cells, Naturally-Occurring
- Naturally-Occurring Suppressor T-Cell
- Naturally-Occurring Suppressor T-Cells
- Suppressor T Cells, Naturally Occurring
- Suppressor T-Cell, Naturally-Occurring
- T-Cell, Naturally-Occurring Suppressor
- T-Cells, Naturally-Occurring Suppressor
Tr1 Cells- Tr1 Cells
- Cell, Tr1
- Cells, Tr1
- Tr1 Cell
|
Below are MeSH descriptors whose meaning is more general than "T-Lymphocytes, Regulatory".
- Anatomy [A]
- Cells [A11]
- Blood Cells [A11.118]
- Leukocytes [A11.118.637]
- Leukocytes, Mononuclear [A11.118.637.555]
- Lymphocytes [A11.118.637.555.567]
- Lymphocyte Subsets [A11.118.637.555.567.550]
- T-Lymphocyte Subsets [A11.118.637.555.567.550.500]
- T-Lymphocytes, Regulatory [A11.118.637.555.567.550.500.700]
- T-Lymphocytes [A11.118.637.555.567.569]
- CD4-Positive T-Lymphocytes [A11.118.637.555.567.569.200]
- T-Lymphocytes, Regulatory [A11.118.637.555.567.569.200.700]
- T-Lymphocyte Subsets [A11.118.637.555.567.569.500]
- T-Lymphocytes, Regulatory [A11.118.637.555.567.569.500.700]
- Hemic and Immune Systems [A15]
- Blood [A15.145]
- Blood Cells [A15.145.229]
- Leukocytes [A15.145.229.637]
- Leukocytes, Mononuclear [A15.145.229.637.555]
- Lymphocytes [A15.145.229.637.555.567]
- Lymphocyte Subsets [A15.145.229.637.555.567.550]
- T-Lymphocyte Subsets [A15.145.229.637.555.567.550.500]
- T-Lymphocytes, Regulatory [A15.145.229.637.555.567.550.500.700]
- T-Lymphocytes [A15.145.229.637.555.567.569]
- CD4-Positive T-Lymphocytes [A15.145.229.637.555.567.569.200]
- T-Lymphocytes, Regulatory [A15.145.229.637.555.567.569.200.700]
- T-Lymphocyte Subsets [A15.145.229.637.555.567.569.500]
- T-Lymphocytes, Regulatory [A15.145.229.637.555.567.569.500.700]
- Immune System [A15.382]
- Leukocytes [A15.382.490]
- Leukocytes, Mononuclear [A15.382.490.555]
- Lymphocytes [A15.382.490.555.567]
- Lymphocyte Subsets [A15.382.490.555.567.550]
- T-Lymphocyte Subsets [A15.382.490.555.567.550.500]
- T-Lymphocytes, Regulatory [A15.382.490.555.567.550.500.700]
- T-Lymphocytes [A15.382.490.555.567.569]
- CD4-Positive T-Lymphocytes [A15.382.490.555.567.569.200]
- T-Lymphocytes, Regulatory [A15.382.490.555.567.569.200.700]
- T-Lymphocyte Subsets [A15.382.490.555.567.569.500]
- T-Lymphocytes, Regulatory [A15.382.490.555.567.569.500.700]
Below are MeSH descriptors whose meaning is more specific than "T-Lymphocytes, Regulatory".
This graph shows the total number of publications written about "T-Lymphocytes, Regulatory" by people in this website by year, and whether "T-Lymphocytes, Regulatory" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 1 | 2 | 3 |
| 2006 | 4 | 0 | 4 |
| 2007 | 3 | 1 | 4 |
| 2008 | 6 | 2 | 8 |
| 2009 | 6 | 0 | 6 |
| 2010 | 7 | 5 | 12 |
| 2011 | 5 | 2 | 7 |
| 2012 | 9 | 3 | 12 |
| 2013 | 6 | 2 | 8 |
| 2014 | 4 | 5 | 9 |
| 2015 | 2 | 2 | 4 |
| 2016 | 8 | 0 | 8 |
| 2017 | 7 | 2 | 9 |
| 2018 | 3 | 1 | 4 |
| 2019 | 7 | 4 | 11 |
| 2020 | 4 | 4 | 8 |
| 2021 | 9 | 5 | 14 |
| 2022 | 4 | 2 | 6 |
| 2023 | 1 | 2 | 3 |
| 2024 | 2 | 2 | 4 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "T-Lymphocytes, Regulatory" by people in Profiles.
-
Gene editing of CD3 epsilon to redirect regulatory T?cells for adoptive T?cell transfer. Mol Ther. 2025 Mar 05; 33(3):997-1013.
-
Neutrophil extracellular traps promote pre-metastatic niche formation in the omentum by expanding innate-like B cells that express IL-10. Cancer Cell. 2025 Jan 13; 43(1):69-85.e11.
-
DNA Methylation-Derived Immune Cell Proportions and Cancer Risk in Black Participants. Cancer Res Commun. 2024 10 01; 4(10):2714-2723.
-
Effector memory-type regulatory T cells display phenotypic and functional instability. Sci Adv. 2024 Sep 06; 10(36):eadn3470.
-
Neoantigen-specific cytotoxic Tr1 CD4 T cells suppress cancer immunotherapy. Nature. 2024 Aug; 632(8023):182-191.
-
A combined radio-immunotherapy regimen eradicates late-stage tumors in mice. Front Immunol. 2024; 15:1419773.
-
Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumors. Cell. 2024 Sep 05; 187(18):4905-4925.e24.
-
Impact of isotype on the mechanism of action of agonist anti-OX40 antibodies in cancer: implications for therapeutic combinations. J Immunother Cancer. 2024 Jul 04; 12(7).
-
Post-immunotherapy CTLA-4 Ig treatment improves antitumor efficacy. Proc Natl Acad Sci U S A. 2024 Jul 02; 121(27):e2404661121.
-
Phase 1 Study of CK0801 in Treatment of Bone Marrow Failure Syndromes. NEJM Evid. 2024 Jun; 3(6):EVIDoa2300362.